Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

被引：0
|
作者：
Peeters, M.
Van Cutsem, E.
Berlin, J.
Hecht, J. R.
Ruiz, R.
Navale, L.
Amado, R.
Meropol, N. J.
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4138
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and tolerability of panitumumab, a fully human monoclonal antibody (MAB), in patients (PTS) with metastatic colorectal cancer (MCRC)
    Hecht, J. Randolph
    Peeters, Marc
    Van Cutsem, Eric
    Berlin, Jordan
    Visonneau, Sophie
    Navale, Lynn
    Ruiz, Rolando
    Amado, Rafael
    Meropol, Neal J.
    ANNALS OF ONCOLOGY, 2006, 17 : 124 - 124
  • [2] Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
    Tubb, E. E.
    Nugent, M.
    Spielberger, J.
    Axelrod, R. A.
    Mitchell, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr).
    Berlin, J.
    Neubauer, M.
    Swanson, P.
    Harker, W. G.
    Burris, H.
    Hecht, J. R.
    Navale, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [4] Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
    Wu, Mel
    Rivkin, Anastasia
    Pham, Trinh
    CLINICAL THERAPEUTICS, 2008, 30 (01) : 14 - 30
  • [5] Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy
    Berlin, J.
    Hecht, J. R.
    Reiner, M.
    Mullenix, M.
    Suggs, S.
    Radinsky, R.
    Freeman, D.
    Amado, R. G.
    Meropol, N. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 241 - 241
  • [6] Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis
    Mitchell, E. P.
    Hecht, J. R.
    Baranda, J.
    Malik, I.
    Richards, D.
    Reiner, M.
    Stout, S.
    Amado, R. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] The safety profile of panitumumab monotherapy in patients with metastatic colorectal cancer (MCRC) across 10 clinical trials
    Knoop, Teresa
    ONCOLOGY NURSING FORUM, 2008, 35 (03) : 491 - 491
  • [8] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
    Gibson, Tara Beers
    Ranganathan, Aarati
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 29 - 31
  • [9] Panitumumab: A fully human monoclonal antibody with activity in metastatic colorectal cancer
    Saadeh, Claire E.
    Lee, H. Stephen
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (04) : 606 - 613
  • [10] Epitope mapping and eludication of the mechanism of action of panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR)
    Freeman, Dan
    Sun, Jilin
    Bass, Randall
    Chong, Ken
    Ogbagabriel, Selam
    Elliott, Gary
    Radinsky, Robert
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3472S - 3472S
12345